how far will this go?, page-42

Morning Anderson 101, PAA have only just completed a Rights Issue for Shareholders , they raised sufficient finance for the completion of Phase II in K9 which positive results would enable the Elanco Option. They have stated that they actually have enough to also begin prelim for Human Trials.

PAA have already been down this exact road,, the Treatment benefits were spectacular but overshadowed by poor palatability.. it's a Re-do but with a Palatable and Higher efficacy formulation..

They also have a $1.2m finance facility that they have been extremely prudent with ,,in fact have been paying down swathes from the Epichem revenue.. so if they fall short for the negotiating period have a cushion.. plus if they asked me for money in the next 3 months I'd gladly dig deep on this one...

Best of luck with your investments ,, the latest update is comprehensive,,, plus Management are about to start to prime the market on awareness,, ergo the Broker conferences ..